OBJECTIVE: The purpose of our work is to assess the role of tumour-to-normal tissue (T/N) dosimetry ratios for predicting response in patients undergoing locoregional therapy to the liver with 90Y microspheres. METHODS: A total of 39 patients (7 female:32 male, mean age 68.3 ± 7.6 years), underwent positron emission tomography (PET)/CT imaging after treatment with 90Y microspheres. For attenuation correction and localization of the 90Y microspheres, the low-dose, non-diagnostic CT images from PET/CT were used. The acquisition took 15 min and the reconstruction matrix size was 200 × 200 × 75 mm and voxel size of 4.07 × 4.07 × 3.00 mm. For dosimetry calculations, the local deposition method with known activity of 90Y was used. For each patient, regions of interest for tumour(s) and whole liver were manually created; the normal tissue region of interest was created automatically. mRECIST criteria on MRI done at 1 month post-treatment and subsequently every 3 months after 90Y treatment, were used to assess response. RESULTS: For 39 patients, the mean liver, tumour and normal tissue doses (mean ± SD) were, 55.17 ± 26.04 Gy, 911.87 ± 866.54 Gy and 47.79 ± 20.47 Gy, respectively. Among these patients, 31 (79%) showed complete response (CR) and 8 (21%) showed progression of disease (PD). For patients with CR, the mean T/N dose ratio obtained was 24.91 (range 3.09-80.12) and for patients with PD, the mean T/N dose ratio was significantly lower, at 6.69 (range 0.36-14.75). CONCLUSION: Our data show that patients with CR have a statistically higher T/N dose ratio than those with PD. Because, the number of PD cases was limited and partial volume effect was not considered, further investigation is warranted. ADVANCES IN KNOWLEDGE: T/N dosimetry ratios can be used for assessing response in patients undergoing locoregional therapy to the liver with 90Y microspheres.
OBJECTIVE: The purpose of our work is to assess the role of tumour-to-normal tissue (T/N) dosimetry ratios for predicting response in patients undergoing locoregional therapy to the liver with 90Y microspheres. METHODS: A total of 39 patients (7 female:32 male, mean age 68.3 ± 7.6 years), underwent positron emission tomography (PET)/CT imaging after treatment with 90Y microspheres. For attenuation correction and localization of the 90Y microspheres, the low-dose, non-diagnostic CT images from PET/CT were used. The acquisition took 15 min and the reconstruction matrix size was 200 × 200 × 75 mm and voxel size of 4.07 × 4.07 × 3.00 mm. For dosimetry calculations, the local deposition method with known activity of 90Y was used. For each patient, regions of interest for tumour(s) and whole liver were manually created; the normal tissue region of interest was created automatically. mRECIST criteria on MRI done at 1 month post-treatment and subsequently every 3 months after 90Y treatment, were used to assess response. RESULTS: For 39 patients, the mean liver, tumour and normal tissue doses (mean ± SD) were, 55.17 ± 26.04 Gy, 911.87 ± 866.54 Gy and 47.79 ± 20.47 Gy, respectively. Among these patients, 31 (79%) showed complete response (CR) and 8 (21%) showed progression of disease (PD). For patients with CR, the mean T/N dose ratio obtained was 24.91 (range 3.09-80.12) and for patients with PD, the mean T/N dose ratio was significantly lower, at 6.69 (range 0.36-14.75). CONCLUSION: Our data show that patients with CR have a statistically higher T/N dose ratio than those with PD. Because, the number of PD cases was limited and partial volume effect was not considered, further investigation is warranted. ADVANCES IN KNOWLEDGE: T/N dosimetry ratios can be used for assessing response in patients undergoing locoregional therapy to the liver with 90Y microspheres.
Authors: Ahsun Riaz; Robert J Lewandowski; Laura M Kulik; Mary F Mulcahy; Kent T Sato; Robert K Ryu; Reed A Omary; Riad Salem Journal: J Vasc Interv Radiol Date: 2009-07-29 Impact factor: 3.464
Authors: Robert Grimm; Sebastian Fürst; Michael Souvatzoglou; Christoph Forman; Jana Hutter; Isabel Dregely; Sibylle I Ziegler; Berthold Kiefer; Joachim Hornegger; Kai Tobias Block; Stephan G Nekolla Journal: Med Image Anal Date: 2014-09-30 Impact factor: 8.545
Authors: C Chiesa; M Maccauro; R Romito; C Spreafico; S Pellizzari; A Negri; C Sposito; C Morosi; E Civelli; R Lanocita; T Camerini; C Bampo; S Bhoori; E Seregni; A Marchianò; V Mazzaferro; E Bombardieri Journal: Q J Nucl Med Mol Imaging Date: 2011-04 Impact factor: 2.346
Authors: Paul Haste; Mark Tann; Scott Persohn; Thomas LaRoche; Vasantha Aaron; Thibault Mauxion; Nikhil Chauhan; Matthew R Dreher; Matthew S Johnson Journal: J Vasc Interv Radiol Date: 2017-02-24 Impact factor: 3.464
Authors: Ravi Murthy; Daniel B Brown; Riad Salem; Steven G Meranze; Douglas M Coldwell; Sunil Krishnan; Rodolfo Nunez; Amit Habbu; David Liu; William Ross; Alan M Cohen; Michael Censullo Journal: J Vasc Interv Radiol Date: 2007-04 Impact factor: 3.464